NASH BIOTECHS 

1. COMMENT ON THE GOLDEN RESULTS PUBLICATION
2. GENFIT AND THE CONJUNCTION OF PLANETS
3. THE BIG PICTURE FOR GENFIT  
4. NASH PATIENTS WITH DIABETES AND CARDIOVASCULAR RISK  NO DOUBT THAT GENFIT'S DRUG CURES NASH
5. NEW NASH FINDINGS FOR GENFIT : EXTENSIVE BIOLOGICAL TESTS SERIOUSLY CHALLENGE PLACEBO-POSITIVE AND ELAFIBRANOR-NEGATIVE BIOPSY RESULTS.
6. THE NEW DEFINITION OF NASH STRIKE THE NASH PLAYERS
7. WHY BIOMARKERS BASED DIAGNOSIS WILL PROFIT TO GENFIT
8. GENFIT'S BIOMARKERS : FROM NASH DIAGNOSIS TO PATIENT CLASSIFICATION ? (by Albert Wright)
9. NEW NASH FINDINGS FOR GENFIT (by Albert Wright)
10. FGF21, A HORMONE MARKER FOR NASH RESPONDERS

This publication reflects the views only of the authors, and he cannot be held responsible for any use which may be made of the information contained therein. The authors of the articles published here are not physician, financial analysts or market professionals. announced data may contain errors, inaccuracies and misinterpretations of facts.The authors could have their own stoks positions on these values. it is therefore recommended to the reader to verify the facts, to inform himself before any investment on listed companies and to make decisions based on his own judgment. The informations and reflections that can be found on this website are by no means of incentives for the purchase or sale of listed securities but personal opinions of the authors, which does not represent the point of view of the mentionned companies    

The main author is not english language native so you can find some gramatical errors or misspelling in the english translated articles.  If you have time you can send corrections to author or better, you can propose a full article correction. 

Positions of G.Divry on the biotech’s mentioned in articles:

GENFIT : H1 2013  - to date:  Long

CONATUS :  to date: No Position

GALT : Jan 2018  - to date: Long

MDGL : to date : No Position